Clinical Trial

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

Study acronym: PRO-NEPA
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial is a prospective, observational, multicenter cohort study evaluating the efficacy and safety of NEPA (netupitant/palonosetron) in patients with HER2-positive or HER2-low advanced breast cancer treated with T-DXd
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-11.
Status change: Not Yet Recruiting → Enrolling by Invitation 2026-01-06
Trial Details
NCT Number NCT07132749
Lead Sponsor Yeon Hee Park
Collaborators: Helsinn Healthcare SA
Conditions Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd, Patients With HER2-low Advanced Breast Cancer Treated With T-DXd
Enrollment 100 participants
Start Date 2025-08-12
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-08